However, most cytological or pathological prognostic factors for patients with DLBCL, such as bcl-2, bcl-6, CD5, CD10, and MUM-1 [16–18], are relatively expensive or time-consuming to implement for general clinical practice, since those measurements can be performed only at specific hospitals or external laboratories. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.